BiotechTube

CPK850

Phase 1/2Active
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Retinitis Pigmentosa

Conditions

Retinitis Pigmentosa

Trial Timeline

Aug 22, 2018 → May 11, 2026

NCT ID
NCT03374657

About CPK850

CPK850 is a phase 1/2 stage product being developed by Novartis for Retinitis Pigmentosa. The current trial status is active. This product is registered under clinical trial identifier NCT03374657. Target conditions include Retinitis Pigmentosa.

What happened to similar drugs?

0 of 3 similar drugs in Retinitis Pigmentosa were approved

Approved (0) Terminated (0) Active (3)
🔄Valganciclovir + GanciclovirRochePhase 3
🔄GanciclovirRochePhase 3
🔄ValganciclovirRochePhase 3

Hype Score Breakdown

Clinical
9
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03374657Phase 1/2Active

Competing Products

20 competing products in Retinitis Pigmentosa

See all competitors
ProductCompanyStageHype Score
DSP-3077 Retinal Sheet Cohort 1 + DSP-3077 Retinal Sheet Cohort 2 + DSP-3077 Retinal Sheet Cohort 3Sumitomo PharmaPhase 1/2
39
AGN-151597AbbViePhase 1/2
32
Valganciclovir + GanciclovirRochePhase 3
40
ValganciclovirRochePre-clinical
26
Foscarnet sodium + GanciclovirRochePhase 1
29
GanciclovirRochePhase 1
29
GanciclovirRochePre-clinical
26
GanciclovirRochePhase 2
35
GanciclovirRochePre-clinical
26
GanciclovirRochePre-clinical
26
Zidovudine + Sargramostim + GanciclovirRochePre-clinical
26
Zidovudine + GanciclovirRochePre-clinical
26
GanciclovirRochePre-clinical
26
Interferon beta-1b + GanciclovirRochePre-clinical
26
GanciclovirRochePre-clinical
26
GanciclovirRochePre-clinical
26
GanciclovirRochePhase 3
40
ValganciclovirRochePhase 3
36
Cidofovir + ProbenecidGilead SciencesPre-clinical
26
Cidofovir + ProbenecidGilead SciencesPre-clinical
26